Pending Acquisition |
9 Months Ended |
---|---|
Sep. 29, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Pending Acquisition | PENDING ACQUISITION On August 28, 2023, the Company entered into a definitive agreement to acquire all of the outstanding shares of Abcam plc (“Abcam”) for a cash purchase price of approximately $5.7 billion, including assumed indebtedness and net of acquired cash (the “Abcam Acquisition”). Abcam is a leading global supplier of protein consumables, including highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research and diagnostics. Abcam generated revenues of £362 million in 2022. The Company expects to include the Abcam business within its Life Sciences segment. The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval. The Company expects to finance the Abcam Acquisition using cash on hand and/or the proceeds from the issuance of commercial paper.
|